Monday, November 30, 2015
Given that over $60 billion of biopharmaceutical sales will lose patent protection by 2020, it is not surprising that most major biologics manufacturers have established biosimilar development programs.
Wednesday, September 30, 2015
Driven by time and cost pressures, the
pharmaceutical industry is increasingly
motivated to develop biopharmaceuticals
for pipeline security because these products
have demonstrated profitability. And as the
development of biologics grows in ...
According to Nice Insight’s 2015 Pharmaceutical
and Biotechnology outsourcing survey, over half of the companies that outsource only to contract resource organizations (CROs) expect they will achieve reductions in project lengths and costs by
using...
Thursday, September 01, 2011
In terms of differentiating from competitors through marketing, CROs and CMOs serving pharmaceutical and biopharmaceutical outsourcing markets need to recognize that data shows there’s a fundamental difference between black and white regulatory ...